SAL

Mesa Labs Acquires GKE-GmbH Complementary Sterilization Indicators and Healthcare Channels to Mesa’s SDC Platform

Retrieved on: 
Monday, October 16, 2023
Hospital, Acquisition, Sterilization, SDC, SAL, Mesa Laboratory, Growth, GKE, Hand, MLAB, Pharmaceutical industry, Waldems

Additionally, Mesa has entered into a definitive agreement to purchase GKE’s Chinese sales entity, Beijing GKE Science & Technology Co. LTD (“GKE China”).

Key Points: 
  • Additionally, Mesa has entered into a definitive agreement to purchase GKE’s Chinese sales entity, Beijing GKE Science & Technology Co. LTD (“GKE China”).
  • “GKE brings a highly competitive portfolio of sterilization indicators to protect patient safety across global healthcare markets which includes hospitals, clinics, and dental services.
  • The combination of GKE’s strength in chemical indicators and healthcare focused sales channels will complement our SDC division’s strength in biologic indicators and life science channels placing both businesses in a position for robust long-term growth.
  • “The combination of GKE with Mesa’s SDC division creates one of the world’s largest sterilization and cleaning process indictor companies.

Checkmarx Streamlines Prioritization and Remediation of Application Vulnerabilities within the ServiceNow Vulnerability Dashboard

Retrieved on: 
Thursday, September 14, 2023
Exploitation, CVE, Avis, Overalls, CVS, SAL, SCA, Risk, ServiceNow, Coordinate system, Risk management, Environmental remediation, Checkmarx

ATLANTA, Sept. 14, 2023 /PRNewswire/ -- Checkmarx, the global leader in cloud-native application security solutions, has announced general availability of an integration that enables AppSec and development teams to discover, prioritize and remediate vulnerabilities found by Checkmarx One™ within the ServiceNow Vulnerability Dashboard.

Key Points: 
  • ATLANTA, Sept. 14, 2023 /PRNewswire/ -- Checkmarx, the global leader in cloud-native application security solutions, has announced general availability of an integration that enables AppSec and development teams to discover, prioritize and remediate vulnerabilities found by Checkmarx One ™ within the ServiceNow Vulnerability Dashboard.
  • The latest vulnerabilities found for each scan are presented within the ServiceNow Vulnerability Dashboard as AVIs (Application Vulnerability Items) for a single view.
  • The Checkmarx ServiceNow integration offers:
    A centralized dashboard to prioritize and remediate: View trends and summaries of scan results to focus on the most critical risks.
  • When Checkmarx provides updated scan results, the ServiceNow Vulnerability Response Application can also automatically assign the found vulnerabilities to a specific person or team by building custom workflows and automation triggers.

ALLOSOURCE LAUNCHES ALLOMEND DUO ACELLULAR DERMAL MATRIX, A NATURAL SOLUTION FOR NON-DIRECTIONAL IMPLANTATION IN SOFT TISSUE RECONSTRUCTION

Retrieved on: 
Thursday, May 25, 2023
ADM, DNA, Antigen, Surgeon, Regeneration, Protein, Patient, Temperature, RNA, SAL, Medical imaging

CENTENNIAL, Colo., May 25, 2023 /PRNewswire/ -- AlloSource®, one of the largest nonprofit allograft providers in the U.S. creating innovative cellular and tissue products to help surgeons heal their patients, today announced the launch of AlloMend® Duo Acellular Dermal Matrix (ADM), a natural solution for soft tissue reconstruction.

Key Points: 
  • CENTENNIAL, Colo., May 25, 2023 /PRNewswire/ -- AlloSource®, one of the largest nonprofit allograft providers in the U.S. creating innovative cellular and tissue products to help surgeons heal their patients, today announced the launch of AlloMend® Duo Acellular Dermal Matrix (ADM), a natural solution for soft tissue reconstruction.
  • NEW AlloMend Duo Acellular Dermal Matrix, a natural solution for non-directional implantation in soft tissue reconstruct
    AlloMend Duo ADM was created to help surgeons repair and reconstruct soft tissue defects for long-term structural support.
  • AlloMend Duo ADM is processed with AlloSource's proprietary DermaTrue™ Decellularization Process to remove cellular debris (including DNA, RNA, proteins and antigens) rendering the tissue acellular.
  • For more information on AlloMend Duo ADM, as well as the other shapes and sizes within the product line, visit allosource.org/products/allomend-duo/ .

Anteriad Report Shows 41% of Marketers Overwhelmed by Pressure to Prove Results

Retrieved on: 
Wednesday, April 26, 2023
Pressure, Hair, Face, Marketing, MQL, Research, CMO, SAL, Cryptocurrency

Ascend2 and Anteriad found that 41% of marketers felt either “overwhelmed” or “ready to pull their hair out” by the pressure to perform.

Key Points: 
  • Ascend2 and Anteriad found that 41% of marketers felt either “overwhelmed” or “ready to pull their hair out” by the pressure to perform.
  • “Our research shows that in the face of mounting pressure to perform, marketers are turning their attention to high-quality data to help drive results.
  • Of marketers surveyed:
    As marketers start to focus on data and insights to help reach goals and prove results, finding the right partner is a critical step.
  • Marketers can turn to partners like Anteriad to create an effective data-driven strategy, and gain access to quality insights like intent data.

STOCKHOLDER ALERT: The M&A Class Action Firm Continues its Investigation of the Merger – MLVF, SAL, ADAP, BRBW

Retrieved on: 
Wednesday, April 5, 2023
ADAP, First Bank, NBT Bank, Empire, SAL, Acquisition, OTC, NBT, Monteverde, Therapy, Security (finance)

Under the terms of the agreement, MLVF shareholders will receive 0.7733 shares of First Bank and $7.80 in cash per share they own.

Key Points: 
  • Under the terms of the agreement, MLVF shareholders will receive 0.7733 shares of First Bank and $7.80 in cash per share they own.
  • It is free and there is no cost or obligation to you.
  • Salisbury Bancorp, Inc. (NASDAQ: SAL ), relating to its proposed merger NBT Bancorp, Inc.
  • Under the terms of the merger, SAL shareholders will receive 0.745 shares of NBT per share they own.

SHAREHOLDER ALERT: The M&A Class Action Firm Continues its Investigation of the Merger – ADAP, SAL, BRBW, MLVF

Retrieved on: 
Wednesday, March 29, 2023
ADAP, NBT Bank, First Bank, Empire, SAL, Acquisition, OTC, NBT, Monteverde, Therapy, Security (finance)

Under the terms of the agreement, ADAP shareholders are expected to own approximately 75% of the combined company.

Key Points: 
  • Under the terms of the agreement, ADAP shareholders are expected to own approximately 75% of the combined company.
  • Salisbury Bancorp, Inc. (NASDAQ: SAL ), relating to its proposed merger NBT Bancorp, Inc.
  • Under the terms of the merger, SAL shareholders will receive 0.745 shares of NBT per share they own.
  • Under the terms of the agreement, MLVF shareholders will receive 0.7733 shares of First Bank and $7.80 in cash per share they own.

BIMINI HEALTH TECH ACQUIRES EXCLUSIVE LICENSE TO ACELLULAR DERMAL MATRIX PRODUCT PORTFOLIO

Retrieved on: 
Tuesday, March 28, 2023
Transfer, ADM, DNA, Acquisition, Standard of care, Patient, Dermis, SAL, Medical imaging

PLANO, Texas, March 28, 2023 /PRNewswire/ -- Bimini Health Tech announced today it has acquired the exclusive rights to an Acellular Dermal Matrix ("ADM") technology for the plastic and reconstructive surgery field of use. 

Key Points: 
  • Acquisition expands Bimini's global soft tissue franchise, which already includes the PureGraft and Dermapose Fat Transfer Systems
    PLANO, Texas, March 28, 2023 /PRNewswire/ -- Bimini Health Tech announced today it has acquired the exclusive rights to an Acellular Dermal Matrix ("ADM") technology for the plastic and reconstructive surgery field of use.
  • The ADM technology is a welcome addition to the 20+ products in our portfolio that are currently approved and cleared around the world."
  • Bimini's offering will be provided in multiple shapes and sizes to meet our customer's needs.
  • By acquiring the exclusive license for this technology, Bimini Health Tech will be able to leverage its existing infrastructure and expertise to bring this important technology to a wider patient population with an estimated U.S. market size over $700 million per year.

BIMINI HEALTH TECH ACQUIRES EXCLUSIVE LICENSE TO ACELLULAR DERMAL MATRIX PRODUCT PORTFOLIO

Retrieved on: 
Tuesday, March 28, 2023
Transfer, ADM, DNA, Acquisition, Standard of care, Patient, Dermis, SAL, Medical imaging

PLANO, Texas, March 28, 2023 /PRNewswire/ -- Bimini Health Tech announced today it has acquired the exclusive rights to an Acellular Dermal Matrix ("ADM") technology for the plastic and reconstructive surgery field of use.

Key Points: 
  • Acquisition expands Bimini's global soft tissue franchise, which already includes the PureGraft and Dermapose Fat Transfer Systems
    PLANO, Texas, March 28, 2023 /PRNewswire/ -- Bimini Health Tech announced today it has acquired the exclusive rights to an Acellular Dermal Matrix ("ADM") technology for the plastic and reconstructive surgery field of use.
  • The ADM technology is a welcome addition to the 20+ products in our portfolio that are currently approved and cleared around the world."
  • Bimini's offering will be provided in multiple shapes and sizes to meet our customer's needs.
  • By acquiring the exclusive license for this technology, Bimini Health Tech will be able to leverage its existing infrastructure and expertise to bring this important technology to a wider patient population with an estimated U.S. market size over $700 million per year.

ALERT: The M&A Class Action Firm Continues its Investigation of the Merger – MLVF, ADAP, BRBW, SAL

Retrieved on: 
Wednesday, March 22, 2023
ADAP, First Bank, NBT Bank, Empire, SAL, Acquisition, OTC, NBT, Monteverde, Therapy, Security (finance)

Under the terms of the agreement, MLVF shareholders will receive 0.7733 shares of First Bank and $7.80 in cash per share they own.

Key Points: 
  • Under the terms of the agreement, MLVF shareholders will receive 0.7733 shares of First Bank and $7.80 in cash per share they own.
  • Adaptimmune Therapeutics plc (NASDAQ: ADAP ), relating to its proposed merger with TCR² Therapeutics Inc.
  • Salisbury Bancorp, Inc. (NASDAQ: SAL ), relating to its proposed merger NBT Bancorp, Inc.
  • Under the terms of the merger, SAL shareholders will receive 0.745 shares of NBT per share they own.

Aziyo Biologics and Sientra Announce SimpliDerm® Partnership to Improve Women’s Access to Biologics for Soft Tissue Reconstruction

Retrieved on: 
Wednesday, March 22, 2023
Partnership, Surgeon, Dermis, SAL, Patient, Risk, Growth, Belay Zeleke, Pharmaceutical industry

Under the agreement terms, Aziyo will grant Sientra certain non-exclusive rights in the United States to market, sell and distribute SimpliDerm for select use in reconstruction surgery.

Key Points: 
  • Under the agreement terms, Aziyo will grant Sientra certain non-exclusive rights in the United States to market, sell and distribute SimpliDerm for select use in reconstruction surgery.
  • “At Aziyo, our mission is to improve compatibility between medical devices and the patients they serve.
  • With this partnership, we significantly expand women’s access to biologic solutions necessary for successful reconstruction procedures,” said Randy Mills, Ph.D., President and Chief Executive Officer of Aziyo Biologics.
  • The partnership with Aziyo allows our customer to access the innovative SimpliDerm portfolio to provide the industry’s most compelling reconstruction portfolio,” said Ron Menezes, President and Chief Executive Officer of Sientra.